Qing Song Sheng
Directeur Général chez Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd.
Provenance du réseau au premier degré de Qing Song Sheng
Entité | Type d'entité | Industrie | |
---|---|---|---|
Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd.
Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. Medical SpecialtiesHealth Technology Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. is a private company that manufactures medical equipment. The company is based in Wuxi, China. The Chinese company was founded in 1999. The CEO is Qing Song Sheng.
5
| Private Company | Medical Specialties | 5 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Qing Song Sheng via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
GEMPHARMATECH CO., LTD. | Biotechnology | Director/Board Member | |
Yale University | College/University | Doctorate Degree | |
JIANGSU HUALAN NEW PHARMACEUTICAL MATERIAL CO.,LTD. | Containers/Packaging | Director/Board Member | |
Genfleet Therapeutics (Shanghai), Inc.
Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017. | Miscellaneous Commercial Services | Director/Board Member | |
Innolake Pharmaceuticals (Hangzhou) Co., Ltd.
Innolake Pharmaceuticals (Hangzhou) Co., Ltd. Pharmaceuticals: MajorHealth Technology Innolake Pharmaceuticals (Hangzhou) Co., Ltd. is a company based in Hangzhou, China that engages in the development and commercialization of therapeutic drugs for tumors and immune system diseases. The Chinese company was founded in 2020 by Ru Lei Chen and Ming De Xia, with Ming De Xia serving as the CEO since 2020. | Pharmaceuticals: Major | Director/Board Member |
Statistiques
Internationale
Chine | 5 |
Etats-Unis | 2 |
Sectorielle
Health Technology | 3 |
Consumer Services | 2 |
Process Industries | 2 |
Commercial Services | 2 |
Opérationnelle
Director/Board Member | 9 |
Doctorate Degree | 1 |
Independent Dir/Board Member | 1 |
Relations les plus connectées
Insiders | |
---|---|
Dan Liu | 6 |
Qing Zhong Tan | 1 |
Jing Jiang | 1 |
Zeng Jiao Sui | 1 |
Yun Feng | 1 |
- Bourse
- Insiders
- Qing Song Sheng
- Connexions Sociétés